<DOC>
	<DOCNO>NCT02135549</DOCNO>
	<brief_summary>To assess safety effectiveness two dos SugarDown two different dos vs. placebo serum glucose level meal subject Type 2 Diabetes treat metformin alone . There five visit , screen visit , baseline visit , 3 treatment visit . The study duration five week . Subjects receive placebo tablet baseline visit , eat standard rice meal , serum glucose level measure frequent interval four hour immediately follow meal . Subjects randomize one six treatment sequence . Patients take unknown order one week placebo , one week 4 g dose one week 8 g dose SugarDown immediately breakfast , lunch dinner meal . Patients continue usual metformin regimen trial period .</brief_summary>
	<brief_title>Study Effectiveness Safety SugarDown v . Placebo Type 2 Diabetic Subjects Treated With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Written inform consent prior trialrelated activity Male female , 2575 year age A diagnosis Type 2 Diabetes least one year prior screen visit Stable daily dose metformin ( 1.7 g daily ) least 3 month prior screen visit Body Mass Index ( BMI ) 25 35 HbA1c 6.5 % 9.0 % Fasting blood glucose &lt; 180 mg/dL Clinically significant cardiovascular , peripheral vascular , cerebrovascular renal disease Any clinical condition apart diabetes Type 2 affect glycemic control , example include diabetes Type 1 , liver disease , chronic pancreatitis , endocrine disease ( e.g . pituitary , thyroid , adrenal gland disease ) , small large intestine motility absorptive disease , active infection , advance malignant tumor bariatric surgery Any concomitant antidiabetic medication metformin , include , limited , follow class medication : insulin , sulfonylurea , glinides , glitazones , alphaglucosidase inhibitor , amylin agonist , DPP4 inhibitor , GLP1 agonists Any concomitant steroid , hormonal , anorexic medication could significantly interfere glycemic control subject Lactating pregnant woman , woman childbearing potential unable use adequate birth control . History patient report illicit drug abuse alcoholism Participation another clinical study one month precede recruitment Any follow laboratory abnormality : AST ALT &gt; 1.5 time upper limit normal liver function test , glomerular filtration rate &lt; 60 ( mL/min/1.73 m2 ) chemistry panel measure MDRD criterion , hemoglobin &lt; 10 g/dL complete blood count</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>